Merge Split Categories

Terms to be merged:

ID: 171, Name: Hypertension

Suggested merge targets:

• Pulmonary Arterial Hypertension

Total pieces of content: 1

• NCT00236665 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension

ID: 261, Name: Lymphoma

Suggested merge targets:

• Lymphoma, Mantle Cell/Small Lymphocytic
• Lymphoma, Non-Hodgkin

Total pieces of content: 1

• NCT01855750 – A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

ID: 180, Name: Neoplasms

Suggested merge targets:

• Neoplasms, Breast
• Neoplasms, Ovarian
• Neoplasms, Prostatic

Total pieces of content: 5

• NCT02165397 – iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström’s Macroglobulinemia
• NCT01009177 – A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine
• NCT01394991 – A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia
• NCT00270166 – A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy
• NCT00270127 – Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving non-Platinum-Containing Chemotherapy